Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Celyad Oncology (CYAD) stocks in Canada

Learn how to easily invest in Celyad Oncology stocks.

Celyad Oncology is a biotechnology business based in the US. Celyad Oncology stocks (CYAD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.71 – an increase of 5% over the previous week. Celyad Oncology employs 95 staff and has a market cap (total outstanding stock value) of $48.8 million.

How to buy stocks in Celyad Oncology

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYAD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Celyad Oncology stock price (NASDAQ:CYAD)

Use our graph to track the performance of CYAD stocks over time.

Celyad Oncology shares at a glance

Information last updated 2022-05-25.
Latest market close$2.10
52-week range$1.51 - $6.40
50-day moving average $2.10
200-day moving average $3.46
Wall St. target price$10.71
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.52

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Celyad Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Celyad Oncology price performance over time

Historical closes compared with the close of $2.1 from 2022-05-26

1 week (2022-05-20) 5.00%
1 month (2022-04-26) 1.94%
3 months (2022-02-25) -34.78%
6 months (2021-11-26) -42.78%
1 year (2021-05-28) -61.96%
2 years (2020-05-28) -80.91%
3 years (2019-05-28) 20.2105
5 years (2017-05-26) 39.96

Celyad Oncology financials

Gross profit TTM $5,000
Return on assets TTM -26.82%
Return on equity TTM -82.13%
Profit margin 0%
Book value $1.64
Market capitalisation $48.8 million

TTM: trailing 12 months

Celyad Oncology share dividends

We're not expecting Celyad Oncology to pay a dividend over the next 12 months.

Celyad Oncology share price volatility

Over the last 12 months, Celyad Oncology's shares have ranged in value from as little as $1.51 up to $6.4. A popular way to gauge a stock's volatility is its "beta".

CYAD.US volatility(beta: 1.19)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad Oncology's is 1.1879. This would suggest that Celyad Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Celyad Oncology overview

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site